ENPICOM Secures Series B Funding

To scale up operations to meet the high demand for its antibody discovery SaaS Platform

ENPICOM, an innovative bioinformatics software engineering company, today announced closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO’s after launch in early 2021.

The additional funds enable the company to scale at a faster pace in this highly attractive market and continuing to deliver innovative product extensions for improved antibody discovery, characterization, and development.

ENPICOM’s IGX Platform is a powerful cloud solution designed to improve immunogenomics research by guiding the discovery and development of superior biotherapeutics. Tailored to the needs of scientists working in antibody discovery, it offers an intuitive environment to combine and manage sequencing data derived from state-of-the-art sequencing technologies (e.g., Sanger, bulk NGS, and Single Cell), integrate assay data from wet-lab experiments, and predict exposed sequence liabilities. All this information can be incorporated into tailored analysis workflows to support candidate selection and prioritization, and significantly improve efficiency and costs of early-stage R&D.

“We are thrilled with this capital injection to further grow our business. It clearly illustrates the trust of our existing investor group, BOM Brabant Ventures, NextGen Ventures, and Arches Capital, in our team and proposition. With the addition of BOP Capital, we have a great new strategic investor on board.” said Jos Lunenberg, Chief Executive Officer at ENPICOM.

“BOP Capital is very proud to join ENPICOM’s investor base. We believe in impact through technology. This is exactly what we see in ENPICOM’s platform. In combination with exceptional leadership and a strong execution track record, this provides a perfect setup to realize future growth in a highly promising market. We are looking forward to becoming part of their journey and work closely with the Enpicom team in the coming years.” said Jeroen Mensen, Managing Partner at BOP Capital.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”